Freenome Closes $270 Million Series C Financing to Advance Novel Multiomics Blood Testing Platform for Early Cancer Detection
Proceeds will accelerate ongoing FDA registrational study of company’s first blood test for colorectal cancer screening and advance product pipeline
Freenome will leverage its unique platform that characterizes both tumor and immune signatures to build next-generation blood screening tests in multiple cancers using the foundation of its colorectal cancer screening test
SOUTH SAN FRANCISCO, Calif., August 26, 2020-- Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood draw, announced an …